Nektar Therapeutics
NKTR
$57.13
$2.284.16%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -35.52M | -41.59M | -50.88M | 7.26M | -37.06M |
| Total Depreciation and Amortization | 196.00K | 214.00K | 426.00K | 332.00K | 993.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -3.27M | -778.00K | 1.55M | -42.27M | -8.93M |
| Change in Net Operating Assets | -10.17M | -3.58M | -146.00K | -11.52M | 1.06M |
| Cash from Operations | -48.76M | -45.74M | -49.05M | -46.19M | -43.93M |
| Capital Expenditure | -114.00K | -37.00K | -2.00K | -459.00K | -666.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | 65.39M | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -94.76M | 49.65M | 43.69M | -4.71M | 46.78M |
| Cash from Investing | -94.87M | 49.62M | 43.69M | 60.21M | 46.12M |
| Total Debt Issued | 142.59M | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 238.00K | 211.00K | 7.00K | 83.00K | 13.00K |
| Repurchase of Common Stock | -- | -- | -- | 0.00 | 0.00 |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -1.15M | -- | -- | 0.00 | 0.00 |
| Cash from Financing | 141.68M | 211.00K | 7.00K | 83.00K | 13.00K |
| Foreign Exchange rate Adjustments | 1.00K | 6.00K | -1.00K | 33.00K | -28.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -1.96M | 4.09M | -5.36M | 14.14M | 2.17M |